Partillion Bioscience Corporation – a life science tools company – recently announced the closing of a $5 million seed financing round, expansion of its board of directors, and a multiyear agreement with Alloy Therapeutics as a Preferred Partner providing antibody discovery services using Partillion’s Nanovial technology. Nanovials handle numerous industry challenges as the first microscale test tubes engineered to isolate and analyze individual cells compatible with standard laboratory equipment.
This investment follows the earlier incubation support from venture studio partners Initiate Studios and General Inception. The funding round also includes participation from new investors ND Capital, Vertical Venture Partners, and Paladin Capital. The proceeds of the funding will be used to accelerate Partillion’s growth and launch new functional single-cell analysis and sorting product lines enabled by its proprietary Nanovial technology.
Along with ND Capital partner Eric Moessinger, Partillion also welcomes to its board Paul Conley, a former board member at 10X Genomics and Twist Bioscience, and CEO of General Inception, and Brad Crutchfield, formerly Chief Commercial Officer at 10X Genomics and President of Bio-Rad’s Life Science Group.
KEY QUOTES:
“We are excited to welcome our new investors and board members who share our vision of democratizing sophisticated single-cell functional assays to unlock new biology and amplify our customers’ therapeutic discovery efforts. This vision is very much reflected in our partnership with Alloy Therapeutics, enabling more pharmaceutical, biotechnology, and even academic labs to have access to sophisticated drug discovery tools.”
- Joe de Rutte, co-founder and CEO of Partillion
“We see Partillion’s products as addressing defined needs in therapeutic discovery, serving as an amplifier for these efforts, including for many of our portfolio companies, but also opening up a whole blue sky of biological discovery based on complex cell functions. We welcome the opportunity for long-term partnership with Partillion.”
- Eric Moessinger, Partner at ND Capital
“We have been pleased by the organic interest in Partillion’s currently available Nanovial products – from academics exploring new biology of secretion to pharmaceutical companies incorporating Nanovials into their therapeutic discovery workflows. In our next phase of growth we aim to further lower the barrier for every life science researcher to access functional cell biology using Nanovials in their workflows.”
- Brad Crutchfield, Partillion Director
“Alloy continues to enable our ecosystem of drug discovery partners with access to the best expertise and technologies for discovering therapeutic antibodies. Partillion’s Nanovial products provide an additional valuable single-cell tool that can be applied in our antibody discovery campaigns for partners.”
- Alloy Therapeutics founder and CEO Errik Anderson
